Generic vs. brand-name drugs
Also known as: generic and brand name medications
A brand-name drug is the original product marketed under a manufacturer's trademarked name, while a generic is a later copy containing the same active ingredient in the same strength, dosage form, and route. Generics must prove bioequivalence to the brand before the FDA approves them.
Every drug has at least two names. The generic name is the nonproprietary name of the active ingredient — atorvastatin, lisinopril, metformin — assigned through a standardized naming process and used by every manufacturer. The brand name is a trademarked name chosen for marketing by the company that developed the drug, such as Lipitor, Zestril, or Glucophage. Brand names are capitalized in writing; generic names are not. A single active ingredient may be sold under many brand names and by many generic manufacturers at once.
The original developer holds patent protection and a period of market exclusivity that lets it recoup development costs before competitors can enter. Once those expire, other manufacturers may seek approval through an abbreviated pathway. They do not repeat the full clinical trial program; instead they must demonstrate bioequivalence, showing that their product delivers the active ingredient to the bloodstream at a comparable rate and extent. The FDA publishes therapeutic equivalence ratings in the Orange Book, where an A rating indicates a product considered substitutable for the brand.
Generics must match the brand in active ingredient, strength, dosage form, and route of administration, and generally in labeled indications — a generic may carve out an indication still under patent — but they may differ in inactive ingredients — dyes, fillers, binders, and preservatives — as well as in shape, color, and imprint. Those differences matter occasionally: a patient with a dye allergy or a specific excipient sensitivity may need a particular product. Because generics avoid the development and marketing costs of the original, they are substantially cheaper, which is why most insurance plans and many state substitution laws encourage or require dispensing them unless the prescriber specifies otherwise. Drugs with a narrow therapeutic index warrant extra care when switching products.
The PTCE tests generic and brand-name recognition heavily. Technicians are expected to match common brand names to their generic equivalents, understand when substitution is permitted, and know that a prescriber must actively indicate dispense-as-written to prevent it.
Key takeaways
- The generic name identifies the active ingredient; the brand name is the manufacturer's trademarked marketing name.
- Generics must contain the same active ingredient, strength, dosage form, and route as the brand.
- Approval requires demonstrating bioequivalence rather than repeating the full clinical trial program.
- Inactive ingredients, appearance, and imprint may legally differ between a generic and the brand.
- Generics cost less, and substitution is generally permitted unless the prescriber marks dispense as written.